When it comes to managing patients with high-risk mantle cell lymphoma, several factors impact their candidacy for CAR T-cell therapy, including time to relapse, TP53 mutation status, age, and even social considerations. Joining Dr. Charles Turck to discuss how we can use these factors to identify patients with high-risk mantle cell lymphoma who would most likely benefit from CAR T-cell therapy is medical oncologist Dr. Tara Graff.